MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025

Reuters

2025/06/18

MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025

MIRA Pharmaceuticals Inc. has announced the publication of a manuscript detailing its lead drug candidate, Ketamir-2, in the peer-reviewed journal Frontiers in Pharmacology. The manuscript, authored by Dr. Itzchak Angel, highlights Ketamir-2 as a novel ketamine analog with a differentiated pharmacological profile. Currently undergoing a Phase 1 clinical trial for neuropathic pain, Ketamir-2 has shown no safety concerns, with dose escalation advancing as planned. MIRA aims to initiate a Phase 2a clinical trial by the end of 2025, subject to regulatory approval. The publication underscores Ketamir-2's potential as a safer alternative to ketamine, with a focus on addressing limitations such as poor oral bioavailability and dissociative side effects. Further scientific data submissions and presentations are in preparation to support its clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040251) on June 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544972759"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544972759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544972759?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544972759","market":"fut","top_or_hot":-1,"title":"MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MIRA Pharmaceuticals Inc. has announced the publication of a manuscript detailing its lead drug candidate, Ketamir-2, in the peer-reviewed journal Frontiers in Pharmacology. The manuscript, authored by Dr. Itzchak Angel, highlights Ketamir-2 as a novel ketamine analog with a differentiated pharmacological profile. Currently undergoing a Phase 1 clinical trial for neuropathic pain, Ketamir-2 has shown no safety concerns, with dose escalation advancing as planned. MIRA aims to initiate a Phase 2a clinical trial by the end of 2025, subject to regulatory approval. The publication underscores Ketamir-2's potential as a safer alternative to ketamine, with a focus on addressing limitations such as poor oral bioavailability and dissociative side effects. Further scientific data submissions and presentations are in preparation to support its clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040251) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-18 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MIRA Pharmaceuticals Inc. has announced the publication of a manuscript detailing its lead drug candidate, Ketamir-2, in the peer-reviewed journal Frontiers in Pharmacology. The manuscript, authored by Dr. Itzchak Angel, highlights Ketamir-2 as a novel ketamine analog with a differentiated pharmacological profile. Currently undergoing a Phase 1 clinical trial for neuropathic pain, Ketamir-2 has shown no safety concerns, with dose escalation advancing as planned. MIRA aims to initiate a Phase 2a clinical trial by the end of 2025, subject to regulatory approval. The publication underscores Ketamir-2's potential as a safer alternative to ketamine, with a focus on addressing limitations such as poor oral bioavailability and dissociative side effects. Further scientific data submissions and presentations are in preparation to support its clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040251) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDLc9fVmL:1","article_id":"2544972759","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544972759","pubTimestamp":1750249851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 18, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIRA":"Mira Pharma"},"translate_title":"MIRA Pharmaceuticals宣布主要候选药物Ketamir-2的1期试验取得进展，准备在2025年底前启动2a期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":0.9},"content_text":"MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025\n    \n\n        MIRA Pharmaceuticals Inc. has announced the publication of a manuscript detailing its lead drug candidate, Ketamir-2, in the peer-reviewed journal Frontiers in Pharmacology. The manuscript, authored by Dr. Itzchak Angel, highlights Ketamir-2 as a novel ketamine analog with a differentiated pharmacological profile. Currently undergoing a Phase 1 clinical trial for neuropathic pain, Ketamir-2 has shown no safety concerns, with dose escalation advancing as planned. MIRA aims to initiate a Phase 2a clinical trial by the end of 2025, subject to regulatory approval. The publication underscores Ketamir-2's potential as a safer alternative to ketamine, with a focus on addressing limitations such as poor oral bioavailability and dissociative side effects. Further scientific data submissions and presentations are in preparation to support its clinical development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040251) on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}